Form 4: Spruce Biosciences Director Granted Stock Options

Spruce Biosciences, Inc. director Muralidhar Bali was granted 30,000 stock options with an exercise price of $0.1162, vesting over one year or upon the 2026 annual meeting.

Summary

• Muralidhar Bali, a Director of Spruce Biosciences, Inc. (SPRB), was granted 30,000 stock options.
• The options have an exercise price of $0.1162 per share.
• The grant date for these options was July 22, 2025.
• The options expire on July 21, 2035.
• Vesting occurs on the first anniversary of the grant date (July 22, 2026), or will be fully vested on the date of the Company's 2026 annual stockholder meeting, contingent on continuous service.
• Full vesting also occurs upon a Change in Control as defined in the 2020 Equity Incentive Plan.

Sentiment

Score: 7

Explanation: The grant of stock options to a director is a positive for corporate governance and aligns interests, indicating stability in board compensation practices. It's a routine event, not indicative of major positive or negative news, hence a neutral-to-slightly positive score.

Positives

• Granting of stock options to a director aligns their interests with those of shareholders, incentivizing long-term performance.
• The options provide a long-term incentive for the director to remain with the company and contribute to its growth.

Risks

• The value of the stock options is dependent on the future stock price of Spruce Biosciences, Inc., which is subject to market fluctuations and company performance.
• Vesting is contingent on continuous service, meaning the director must remain with the company to realize the full benefit of the options.

Future Outlook

The stock options are designed to incentivize the director's continuous service and align their interests with long-term company performance, with vesting tied to future dates and events like the 2026 annual stockholder meeting or a change in control.

Industry Context

This transaction is a routine compensation event for a director in a publicly traded biotechnology company, reflecting standard practices for aligning executive and board member incentives with shareholder value through equity grants.

Comparison to Industry Standards

• Granting stock options to directors is a common practice across the biotechnology and broader public company sectors to attract and retain talent and align interests.
• The specific number of options (30,000) and exercise price ($0.1162) would typically be evaluated against peer companies of similar market capitalization and stage of development, though specific comparable companies are not mentioned in the filing.
• Vesting schedules tied to service and accelerated vesting upon a change in control are standard provisions in equity incentive plans across industries.

Corporate Governance

Related Party Transactions

• The grant of stock options to a director is a related party transaction, as directors are considered related parties to the company. This is a standard form of compensation.

Stakeholder Impact

• Shareholders: The grant aligns the director's financial interests with shareholder value creation, potentially leading to better long-term performance.

Next Steps

• The stock options will begin vesting on July 22, 2026, or earlier upon the Company's 2026 annual stockholder meeting.
• The options will fully vest upon a Change in Control, as defined in the 2020 Equity Incentive Plan.

Key Dates

Recommendation

This Form 4 filing reports a routine stock option grant to a director, which is a standard compensation practice. It does not contain information significant enough to warrant a change in investment recommendation for a seasoned investor or institution, as it reflects normal course of business rather than a material operational or financial event.

Keywords

Spruce Biosciences, SPRB, Stock Options, Director Compensation, Equity Incentive Plan, Form 4, Insider Transaction, Muralidhar Bali